Gaurav Munj 2022-03-04T06:42:16+00:00 Press Releases Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Historical Lookup Governance Documents Committees Year None202420232022 December 16, 2024 Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates December 6, 2024 Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting November 25, 2024 Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity November 12, 2024 Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments October 2, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares October 1, 2024 Biohaven Announces Pricing of $250 Million Public Offering of Common Shares September 30, 2024 Biohaven Announces Proposed Public Offering of Common Shares September 30, 2024 Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine September 23, 2024 Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) September 20, 2024 Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia Current page 1 Page 2 Page 3 ► ► Displaying 1 - 10 of 21 BIOHAVEN (BHVN) Volume Market Cap 52 Week High 52 Week Low Minimum 15 minutes delayed. Source: LSEG
Year None202420232022 December 16, 2024 Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates December 6, 2024 Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting November 25, 2024 Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity November 12, 2024 Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments October 2, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares October 1, 2024 Biohaven Announces Pricing of $250 Million Public Offering of Common Shares September 30, 2024 Biohaven Announces Proposed Public Offering of Common Shares September 30, 2024 Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine September 23, 2024 Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) September 20, 2024 Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia Current page 1 Page 2 Page 3 ► ► Displaying 1 - 10 of 21
December 16, 2024 Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
December 6, 2024 Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
November 25, 2024 Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
November 12, 2024 Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
October 2, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
September 30, 2024 Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
September 23, 2024 Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
September 20, 2024 Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
